SpaceX's post-IPO slide suggests the market is starting to price in the risk, not just the dream

SpaceX closed below its $150 IPO price for the second straight day even as Cathie Wood bought in, Raymond James slapped an $800 price target on it, and the company announced a $60 billion acquisition of AI coding platform Cursor alongside a new AI product launch.

The problem is that a price-to-sales ratio north of 100 leaves no room for disappointment, and when a legendary investor like Jeremy Grantham publicly warns of a historic collapse, even true believers start doing the math.

Strong order momentum at Boeing cannot translate to revenue until the factory output gap closes

Boeing is closing in on a deal to sell 10 wide-body jets to Etihad Airways, expected to be announced at this month's Farnborough Airshow, while simultaneously opening a fourth 737 MAX assembly line to expand production capacity.

The catch is that Boeing is building 42 planes a month against a backlog sized for 72 to 80, meaning the revenue upside everyone is excited about only materializes if the company can fix its manufacturing pace first.

ResMed's software sale looks less like strategic focus and more like a retreat the market wasn't buying

ResMed announced the $490 million sale of its MatrixCare software unit to Frazier Healthcare Partners, framing the move as a sharpening of focus on sleep and home-based care.

But the stock's sharp drop on the day of a supposedly good announcement is the market's verdict that ResMed has not yet proven its growth story still holds.